Ovagen

Ovagen is a synthetic tripeptide bioregulator (Glu-Asp-Leu, EDL) developed by Professor Vladimir Khavinson targeting the liver and gastrointestinal tract. It is classified as a hepatoprotective bioregulator studied for its ability to promote hepatic cell regeneration, reduce liver fibrosis, and protect the GI mucosal lining. It is part of the Khavinson family of cytomaxes and cytogens.

Ovagen is transported into cells via POT family peptide transporters (PEPT1, PEPT2), which selectively handle di- and tripeptides, conferring tissue-specific delivery to hepatocytes and intestinal epithelial cells. Once intracellular, Ovagen crosses the nuclear membrane and interacts directly with DNA in target tissue, modulating transcription of genes involved in cell proliferation, fibrogenesis, and hepatocellular metabolism. In aged hepatic tissue, Ovagen increases Ki-67 expression (a proliferation marker) by up to 18-fold while simultaneously reducing p53 expression by up to 6-fold, favoring regenerative over apoptotic signaling. It inhibits fibroblast-driven fibrotic changes at the cellular level, preventing progressive scarring. In the GI tract, it protects the mucosal layer from antibiotic damage, environmental toxins, and chemotherapy-induced injury.

Preclinical research from the Khavinson group demonstrates significant hepatoprotective effects in aged animal liver tissue, including stimulation of hepatocyte proliferation, reduction in liver fibrosis markers, and cytoprotection against hepatotoxic insults. GI mucosal protection studies show reduced injury from toxic exposures. Human research is limited to Russian observational studies and clinical series without randomized controlled trial designs meeting Western regulatory standards. No large RCTs exist in the English-language literature.

Peptides commonly paired with Ovagen for synergistic effects.